NEW YORK, Jan 29 – Sequitir said Monday it signed a multi-year, multi-million dollar deal to supply Bristol-Myers Squibb with its antisense compounds for target validation and to perform biological screening for the pharmaceutical company.
" We are excited to begin a large scale agreement with Bristol-Myers Squibb based on the successful completion of an agreement last year,” Tod Woolf, Sequitur's vice president of technology development, said in a statement. “We are particularly excited by the high throughput phenotypic target validation screening to be performed with Bristol-Myers Squibb.”
Woolf said the deal would result in the development of more than 1,000 antisense compounds that would be added to the company’s OmniScreen library.
Financial terms of the deal were not disclosed.
Sequitur's technology is used to discover and validate genes. Antisense inhibits gene expression, allowing researchers to better understand gene function and validate small molecule drug targets.
Privately held Sequitur of Natick, Mass., generally receives upfront licensing and milestone fees. In addition to OmniScreen, the company also offers GeneLink, a pathway elucidation technology.
Sequitir’s customers include Incyte Genomics, Amgen, and AstraZeneca.